News | February 20, 2022
GSK pauses phase III RSV maternal vaccine candidate programme
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Subscribe To Our Newsletter & Stay Updated
